Medical Devices: What Those Paying Are Saying

The Affordable Care Act is shifting the economic risks of care from the payors to the providers, and medtech companies will be forced to find new sales and distribution channels, new ways of defining clinical and economic benefit, and new offerings wrapped around devices to enhance both their clinical and economic value. At the IN3 meeting in October 2013, executives from both the payor and provider communities discussed how medtech companies should respond to these new dynamics.

Lisa Suennen, a partner at the venture capital firm the Psilos Group, has sat through countless pitches from medical device companies seeking funding. Psilos is a diversified fund focused on health care, and its current $300 million fund invests across health care services, health care IT, and medical devices, with medical devices tending to account for 34% of the mix. Before becoming a founding partner of Psilos in 1998, Suennen had spent 10 years as an executive at Merit Behavioral Care, a specialty health care management organization. Because she operates in both the service and medical device worlds, Suennen says she has realized how insular the thinking of the medical device world is and how out of sync it is with the way health systems operate. “I often see medtech start-ups focused on getting a reimbursement code. But getting a code isn’t the same thing as getting it paid for and too few really understand that.”

Medtech companies are certainly sensitive to the pressures of health care reform and they’re conscious that their products need to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Future Proofing Gene Therapy Assays For Regulatory Success

 
• By 

As gene therapy advances and regulations tighten, biopharma companies face growing pressure to design diagnostic assays that are both flexible and future ready. Strategic early investment in assay development can prevent costly delays and rework as therapies progress toward approval.

Podcast: Poolbeg CEO On The Biotech’s Big Bet On Small Molecules

 
• By 

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG